Quarterly report · Q2
2269.TEDINET S100S7SR
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥546.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥1.06T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥517.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥44.4bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥43.2bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥43.4bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥74.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥43.9bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥48.1bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥48.3bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥27.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥69.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥33.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥30.4bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥34.9bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥1.21T | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥1.14T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.18T | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥421.1bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥384.9bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥786.7bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥751.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥757.0bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥82.1bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥63.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥78.4bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥60.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥88.7bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥64.9bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥25.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥85.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥25.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥15.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥36.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥26.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥4.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥54.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥20.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥100.13 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥58.54 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥247.39 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.52 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥61.65 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 61.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.7% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.6% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥303m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥303m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.1bn |
| jpcrp040300-q2r_E21902-000Foodreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥445.5bn |
| jpcrp040300-q2r_E21902-000Foodreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥445.2bn |
| jpcrp040300-q2r_E21902-000Foodreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥293m |
| jpcrp040300-q2r_E21902-000Foodreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥29.7bn |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥100.9bn |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥100.8bn |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥9m |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥15.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥546.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥546.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥303m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥45.6bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥292m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥292m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥786m |
| jpcrp040300-q2r_E21902-000Foodreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥420.6bn |
| jpcrp040300-q2r_E21902-000Foodreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥420.4bn |
| jpcrp040300-q2r_E21902-000Foodreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥278m |
| jpcrp040300-q2r_E21902-000Foodreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥29.3bn |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥97.2bn |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥97.2bn |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥13m |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥14.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥517.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥517.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥292m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥44.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 552
| Item | Context | Value | Unit |
|---|---|---|---|
| Retained earnings | CurrentQuarterInstant | 616662000000 | JPY |
| Treasury stock | Prior1YearInstant | -47502000000 | JPY |
| Treasury stock | CurrentQuarterInstant | -38229000000 | JPY |
| Shareholders equity | Prior1YearInstant | 665149000000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 680842000000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 31598000000 | JPY |
| Valuation difference on available for sale securities | CurrentQuarterInstant | 36106000000 | JPY |
| Deferred gains or losses on hedges | Prior1YearInstant | 11000000 | JPY |
| Deferred gains or losses on hedges | CurrentQuarterInstant | 185000000 | JPY |
| Foreign currency translation adjustment | Prior1YearInstant | 17870000000 | JPY |
| Foreign currency translation adjustment | CurrentQuarterInstant | 30663000000 | JPY |
| Remeasurements of defined benefit plans | Prior1YearInstant | -2713000000 | JPY |
| Remeasurements of defined benefit plans | CurrentQuarterInstant | -2530000000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 46767000000 | JPY |
| Valuation and translation adjustments | CurrentQuarterInstant | 64425000000 | JPY |
| Non controlling interests | Prior1YearInstant | 39394000000 | JPY |
| Non controlling interests | CurrentQuarterInstant | 41418000000 | JPY |
| Net assets | Prior1YearInstant | 751311000000 | JPY |
| Net assets | CurrentQuarterInstant | 786685000000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 1136217000000 | JPY |
| Liabilities and net assets | CurrentQuarterInstant | 1207796000000 | JPY |
| Net sales | Prior1YTDDuration | 517520000000 | JPY |
| Net sales | CurrentYTDDuration | 546047000000 | JPY |
| Cost of sales | Prior1YTDDuration | 362045000000 | JPY |
| Cost of sales | CurrentYTDDuration | 383541000000 | JPY |
| Gross profit | Prior1YTDDuration | 155474000000 | JPY |
| Gross profit | CurrentYTDDuration | 162505000000 | JPY |
| Selling general and administrative expenses | Prior1YTDDuration | 112281000000 | JPY |
| Selling general and administrative expenses | CurrentYTDDuration | 118061000000 | JPY |
| Operating income | Prior1YTDDuration | 43193000000 | JPY |
| Operating income | CurrentYTDDuration | 44443000000 | JPY |
| Interest income noi | Prior1YTDDuration | 164000000 | JPY |
| Interest income noi | CurrentYTDDuration | 239000000 | JPY |
| Dividends income noi | Prior1YTDDuration | 787000000 | JPY |
| Dividends income noi | CurrentYTDDuration | 735000000 | JPY |
| Equity in earnings of affiliates noi | Prior1YTDDuration | 628000000 | JPY |
| Equity in earnings of affiliates noi | CurrentYTDDuration | － | JPY |
| Foreign exchange gains noi | Prior1YTDDuration | － | JPY |
| Foreign exchange gains noi | CurrentYTDDuration | 139000000 | JPY |
| Other noi | Prior1YTDDuration | 785000000 | JPY |
| Other noi | CurrentYTDDuration | 710000000 | JPY |
| Non operating income | Prior1YTDDuration | 2366000000 | JPY |
| Non operating income | CurrentYTDDuration | 1824000000 | JPY |
| Interest expenses noe | Prior1YTDDuration | 241000000 | JPY |
| Interest expenses noe | CurrentYTDDuration | 202000000 | JPY |
| Equity in losses of affiliates noe | Prior1YTDDuration | － | JPY |
| Equity in losses of affiliates noe | CurrentYTDDuration | 1521000000 | JPY |
| Other noe | Prior1YTDDuration | 1404000000 | JPY |
| Other noe | CurrentYTDDuration | 1110000000 | JPY |
| Non operating expenses | Prior1YTDDuration | 1646000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |